Company news
Alto Neuroscience, Inc. news in 2026
Alto Neuroscience, Inc.'s news releases, calls and decks from 2026, newest first.
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
November 10, 2026
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
November 4, 2026
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
November 3, 2026
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
August 27, 2026
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
July 13, 2026
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
June 15, 2026
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
May 28, 2026
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
May 15, 2026
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
May 4, 2026
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
April 21, 2026
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
April 1, 2026
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
March 23, 2026
Alto Neuroscience Announces $120 Million Private Placement Financing
March 16, 2026
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
March 16, 2026
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
March 13, 2026
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
February 23, 2026
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
February 13, 2026
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
February 3, 2026
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
January 14, 2026
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
January 13, 2026
Corporate Presentation
January 12, 2026
Decks in 2026
- Investor Presentation (January 2026)
Investor deck · 70 slides · January 2026